Blueblood Ventures Limited Schedules Board Meeting on May 27, 2026 to Approve FY26 Financial Results

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Blueblood Ventures Limited has intimated BSE Limited of a board meeting on May 27, 2026, at its New Delhi office, to approve audited standalone financial results for the half year and financial year ended March 31, 2026, under Regulation 29 of SEBI (LODR) Regulations, 2015. The trading window for designated persons has been closed since March 31, 2026, and is set to reopen on May 30, 2026.

powered bylight_fuzz_icon
40397594

*this image is generated using AI for illustrative purposes only.

Blueblood Ventures Limited has notified BSE Limited of an upcoming board meeting scheduled for Wednesday, May 27, 2026, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was submitted to the Secretary of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Board Meeting Details

The board meeting will be held at the company's registered address at M-55, Third Floor, Greater Kailash-II, New Delhi – 110048. The key agenda item for the meeting is outlined below:

Parameter: Details
Meeting Date: Wednesday, May 27, 2026
Venue: M-55, Third Floor, Greater Kailash-II, New Delhi – 110048
Agenda: Approval of Audited Standalone Financial Results
Period Under Review: Half year and financial year ended March 31, 2026
Regulatory Basis: Regulation 29, SEBI (LODR) Regulations, 2015

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code for regulating, monitoring, and reporting of trading in securities by designated persons, the trading window for all designated persons, including insiders, has been closed with effect from March 31, 2026. The trading window is scheduled to reopen on May 30, 2026.

Regulatory Compliance

The intimation was signed by Suresh Bohra, Managing Director of Blueblood Ventures Limited, and submitted for the information and records of BSE Limited. The company's contact details are as follows:

How might Blueblood Ventures Limited's audited standalone financial results for FY2026 compare to its previous year's performance, and what growth trajectory could investors expect?

Will the board meeting on May 27, 2026 include any additional agenda items beyond financial results approval, such as dividend declarations or strategic announcements?

How could the trading window reopening on May 30, 2026 impact the stock's trading volume and price volatility following the release of the audited results?

like18
dislike

Blueblood Ventures Limited Files SEBI Compliance Certificate for Q4FY26

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Blueblood Ventures Limited submitted its quarterly SEBI compliance certificate for Q4FY26 ended March 31, 2026, under Regulation 74(5) of SEBI (Depository Participant) Regulations. The certificate, signed by Managing Director Suresh Bohra and filed with BSE Limited on April 8, 2026, confirms no physical share certificates were received for dematerialization during the quarter. Skyline Financial Services Private Limited, the company's RTA, provided the confirmation certificate.

powered bylight_fuzz_icon
37218293

*this image is generated using AI for illustrative purposes only.

Blueblood Ventures Limited has fulfilled its quarterly regulatory obligations by submitting a compliance certificate under SEBI (Depository Participant) Regulations to BSE Limited. The submission, dated April 8, 2026, covers the quarter ended March 31, 2026, and demonstrates the company's adherence to mandatory reporting requirements.

Regulatory Compliance Details

The certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to report on dematerialization activities during each quarter. Managing Director Suresh Bohra (DIN: 00093343) signed the submission on behalf of Blueblood Ventures Limited.

Parameter: Details
Reporting Quarter: Q4FY26 ended March 31, 2026
Filing Date: April 8, 2026
Regulation: SEBI Regulation 74(5)
Signatory: Suresh Bohra, Managing Director
Exchange: BSE Limited

Certificate Confirmation

Skyline Financial Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA), issued the confirmation certificate dated April 1, 2026. The certificate confirms that no physical share certificates were received for dematerialization of equity shares during the quarter ended March 31, 2026.

Parveen Sharma, Authorised Signatory of Skyline Financial Services Private Limited, signed the certificate confirming the dematerialization status for Blueblood Ventures Limited (CIN: L70102DL2007PLC159680).

Company Information

Blueblood Ventures Limited maintains its registered office at M-55, 3rd Floor M-Block Market Greater Kailash-II New Delhi 110048. The company operates under the email address blueblood@blackfoxindia.com and maintains its corporate website at www.bluebloodventure.com .

The quarterly filing represents standard regulatory compliance, ensuring transparency in the company's share dematerialization processes and maintaining good standing with market regulators.

What factors might be driving the absence of physical share dematerialization requests for Blueblood Ventures in Q4FY26?

How will SEBI's evolving regulatory framework for depositories impact Blueblood Ventures' compliance costs in FY27?

What strategic initiatives might Blueblood Ventures pursue to increase investor engagement and trading activity?

like17
dislike

More News on Blueblood Ventures Limited